FDA Clears Oricula Therapeutics Investigational New Drug Application for Clinical Trials

ORC-13661 Could be the First Medicine Approved Specifically to Prevent Hearing Loss of Patients Using Certain Antibiotics SEATTLE, Feb. 5, 2018 -- (Healthcare Sales & Marketing Network) -- ORICULA THERAPEUTICS, LLC., a biotech company introducing medic... Biopharmaceuticals, FDA Oricula Therapeutics, ORC-13661, hearing loss
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news